GURUFOCUS.COM » STOCK LIST » USA » NYSE » Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) » Definitions » Days Sales Outstanding
Switch to:

Biohaven Pharmaceutical Holding Co Days Sales Outstanding

: 144.42 (As of Jun. 2022)
View and export this data going back to 2017. Start your Free Trial

Biohaven Pharmaceutical Holding Co's average Accounts Receivable for the three months ended in Jun. 2022 was $340.4 Mil. Biohaven Pharmaceutical Holding Co's Revenue for the three months ended in Jun. 2022 was $215.1 Mil. Hence, Biohaven Pharmaceutical Holding Co's Days Sales Outstanding for the three months ended in Jun. 2022 was 144.42.

The historical rank and industry rank for Biohaven Pharmaceutical Holding Co's Days Sales Outstanding or its related term are showing as below:

BHVN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 119.79   Med: 429.03   Max: 689.02
Current: 119.79

During the past 7 years, Biohaven Pharmaceutical Holding Co's highest Days Sales Outstanding was 689.02. The lowest was 119.79. And the median was 429.03.

BHVN's Days Sales Outstanding is ranked worse than
73.17% of 876 companies
in the Biotechnology industry
Industry Median: 71.46 vs BHVN: 119.79

Biohaven Pharmaceutical Holding Co's Days Sales Outstanding declined from Jun. 2021 (159.76) to Jun. 2022 (144.42).


Biohaven Pharmaceutical Holding Co Days Sales Outstanding Historical Data

The historical data trend for Biohaven Pharmaceutical Holding Co's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Pharmaceutical Holding Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Days Sales Outstanding
Premium Member Only Premium Member Only - - - 689.02 169.03

Biohaven Pharmaceutical Holding Co Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Days Sales Outstanding Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 159.76 141.70 134.76 91.09 144.42

Competitive Comparison

For the Biotechnology subindustry, Biohaven Pharmaceutical Holding Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biohaven Pharmaceutical Holding Co Days Sales Outstanding Distribution

For the Biotechnology industry and Healthcare sector, Biohaven Pharmaceutical Holding Co's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Biohaven Pharmaceutical Holding Co's Days Sales Outstanding falls into.



Biohaven Pharmaceutical Holding Co Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Biohaven Pharmaceutical Holding Co's Days Sales Outstanding for the fiscal year that ended in Dec. 2021 is calculated as

Days Sales Outstanding (A: Dec. 2021 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2020 ) + Accounts Receivable (A: Dec. 2021 )) / count ) / Revenue (A: Dec. 2021 )*Days in Period
=( (120.111 + 308.269) / 2 ) / 462.509*365
=214.19 / 462.509*365
=169.03

Biohaven Pharmaceutical Holding Co's Days Sales Outstanding for the quarter that ended in Jun. 2022 is calculated as:

Days Sales Outstanding (Q: Jun. 2022 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Mar. 2022 ) + Accounts Receivable (A: Jun. 2022 )) / count ) / Revenue (A: Jun. 2022 )*Days in Period
=( (328.342 + 352.449) / 2 ) / 215.079*365 / 4
=340.3955 / 215.079*365 / 4
=144.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohaven Pharmaceutical Holding Co  (NYSE:BHVN) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Biohaven Pharmaceutical Holding Co Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Biohaven Pharmaceutical Holding Co's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven Pharmaceutical Holding Co Business Description

Biohaven Pharmaceutical Holding Co logo
Traded in Other Exchanges
Address
C/o Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT, USA, 06510
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.
Executives
Antonijevic Irina director 215 CHURCH STREET NEW HAVEN CT 06510
Buten Matthew officer: Officer 215 CHURCH STREET NEW HAVEN CT 06510
Clark George C. officer: VP, Chief Accounting Officer 215 CHURCH STREET NEW HAVEN CT 06510
Mehta Kishan director 540 WEST 49TH STREET UNIT# PH1N NEW YORK NY 10019
Hugin Robert J director C/O THE MEDICINES CO 8 CAMPUS DR PARSIPPANY NJ 07054
Heffernan Michael Thomas director C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Stock Elyse officer: Chief Medical Officer 215 CHURCH STREET NEW HAVEN CT 06510
Jones William A Jr officer: CCO-Migraine & Common Disease NITROMED, INC. 125 SPRING STREET LEXINGTON MA 02421
Repella Robert director 1410 PARSONS LANE AMBLER PA 19002
Gregory Julia P director 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381
Gentile Kimberly officer: VP of Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Childs John W director, 10 percent owner 111 HUNTINGTON AVENUE SUITE 2900 BOSTON MA 02199
Berman Robert officer: Chief Medical Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Doogan Declan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Tilton John officer: Chief Commercial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510

Biohaven Pharmaceutical Holding Co Headlines

From GuruFocus

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)